Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.8252W HIGH $127.50
Volume
29.09 K
Value Traded
304.55 K
Short % Float
24.24%
Days to Cover
1.0
-22.71%Week
-76.77%1 Month
-87.11%3 Month
-86.45%6 Month
-90.32%5 Year
-90.32%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
2.78 M
EPS (TTM)
-39.51
P/E Ratio
-
Ent. Value
-12.39 M
Total Shares
1.43 M
Float Shares
180.00 K
Insiders
22.91%
Institutions
26.74%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
PoA blends historical approval base rates, trial design score and FDA review track record.
MDCX Catalyst Timeline
Dated clinical, regulatory and corporate events for Medicus Pharma Ltd.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Medicus Pharma Ltd.
241Total events
25Upcoming
56Tier-1 (high impact)
2023 to 2026Coverage
Upcoming catalysts 2
Event history 50
▲Stock ListingCorporate
Medicus Pharma regains compliance with Nasdaq $1.00 minimum bid price requirement
●Timing GuidanceTeverelix®FiledPresentation
Medicus submits optimized seamless Phase 2b/3 registration-intent protocol for Teverelix in APC to FDA
advanced prostate cancersource ↗
▼Program DiscontinuationSkinJect®DiscontinuedCorporate
Medicus concludes further SkinJect development in sporadic/nodular BCC to focus exclusively on Gorlin syndrome
sporadic/nodular basal cell carcinomasource ↗
●Pipeline PrioritizationSkinJect®DiscontinuedCorporate
Medicus prioritizes SkinJect exclusively for Gorlin syndrome with multiple BCC lesions
Gorlin syndromesource ↗
●Timing GuidanceSkinJect®DiscontinuedPresentation
Medicus to focus future internally sponsored SkinJect development exclusively on Gorlin syndrome and conclude nBCC development
Gorlin syndrome with multiple basal cell carcinoma lesionssource ↗
▲Full ResultsSkinJect®DiscontinuedClinical Data
Abridged final Phase 2 CSR for SKNJCT-003 posted on ClinicalTrials.gov
nodular basal cell carcinomasource ↗
▲Trial InitiationSkinJect®DiscontinuedTrial
FDA authorizes initiation of SKNJCT-005 registrational Phase 2b study in Gorlin syndrome
Gorlin syndromesource ↗
▲Pipeline PrioritizationCD228VCorporate
CD228V becomes principal strategic priority with initial focus on melanoma
melanomasource ↗
▲Pipeline PrioritizationSkinJect®DiscontinuedCorporate
SkinJect development focused on Gorlin syndrome rather than sporadic BCC
Gorlin syndromesource ↗
▲Pipeline PrioritizationTeverelix®FiledCorporate
Teverelix Phase 2 AUR program prioritized
acute urinary retentionsource ↗
●Timing GuidanceSkinJect®DiscontinuedPresentation
Company announced capital-efficient portfolio strategy identifying Gorlin syndrome as strongest development opportunity for SkinJect
Gorlin syndromesource ↗
▲IND ClearanceTeverelix®FiledIND
UAE DOH grants IND authorization for PRECISION-E2 study
endometriosissource ↗
▲Trial InitiationSkinJect®DiscontinuedTrial
Initiation of NDA-enabling registrational Phase 2b study SKNJCT-005
Gorlin Syndrome with multiple basal cell carcinomassource ↗
▲Timing GuidanceSkinJect®DiscontinuedPresentation
FDA issued Study May Proceed letter authorizing initiation of SKNJCT-005 NDA-enabling Phase 2b study
Gorlin syndromesource ↗
▲IND ClearanceSkinJect®DiscontinuedIND
FDA issues 'Study May Proceed' letter for IND for SKNJCT-005
Gorlin Syndrome with multiple basal cell carcinomassource ↗
▲IND ClearanceSKNJCT-005IND
FDA issued 'Study May Proceed' letter for SKNJCT-005 IND
Gorlin Syndromesource ↗
▲FDA Feedback ReceivedTeverelix®FiledFDA Meeting
FDA written feedback on optimized Phase 2 protocol
acute urinary retentionsource ↗
▲Topline ReadoutSkinJect®DiscontinuedClinical Data
Positive decision-grade dataset from Phase 2 SKNJCT-003 study
basal cell carcinomasource ↗
▲Trial InitiationTeverelix®FiledTrial
Initiation of PRECISION-E2 Phase 2a study in endometriosis
endometriosissource ↗
●Timing GuidanceTeverelix®FiledPresentation
Submission of substantial modification application via CTIS for planned Phase 2b dose-optimization study
advanced prostate cancersource ↗
▲Trial InitiationTeverelix®FiledTrial
Central IRB approval received for Phase 2 study
acute urinary retentionsource ↗
▲IND ClearanceTeverelix®FiledIND
Central IRB approval with modifications
acute urinary retentionsource ↗
●Information RequestSkinJect®DiscontinuedRegulatory Filing
FDA information requests on June 18, 2026
Gorlin Syndrome with multiple basal cell carcinomassource ↗
◆Rare Pediatric DiseaseSkinJect®DiscontinuedDesignation
Rare Pediatric Disease Designation request submitted to FDA for SkinJect in Gorlin Syndrome
Gorlin Syndromesource ↗
◆Orphan Drug DesignationSkinJect®DiscontinuedDesignation
Orphan Drug Designation application submitted for SkinJect in Gorlin Syndrome
Gorlin Syndromesource ↗
▲Trial CompletionSkinJect®DiscontinuedTrial
Phase 2 study completed for SkinJect in nodular BCC
basal cell carcinomasource ↗
◆FDA Feedback ReceivedSkinJect®DiscontinuedFDA Meeting
Registrational study design (SKNJCT-005) under FDA review
Gorlin Syndromesource ↗
●IND SubmissionTeverelix®FiledIND
IND submission to Department of Health, Abu Dhabi for PRECISION-E2 Phase 2a study of Teverelix in endometriosis
endometriosissource ↗
▲Other Regulator MilestoneTeverelix®FiledEx-US Regulatory
Submitted substantial modification application via CTIS for planned Phase 2b study of Teverelix in advanced prostate cancer
advanced prostate cancersource ↗
●IND SubmissionSkinJect®DiscontinuedIND
Submission of Protocol SKNJCT-005 to FDA under existing IND
Gorlin Syndromesource ↗
▲Debt Royalty FinancingCorporate
Up to $22 million non-dilutive structured financing facility
▲Full ResultsClinical Data
Pre-specified expanded Phase 2 SKNJCT-003 data analysis demonstrating positive dose-response
nodular basal cell carcinomasource ↗
▲Topline ReadoutClinical Data
Positive topline results from SKNJCT-003 study in 90 randomized patients
nodular basal cell carcinomasource ↗
◆Poster PresentationTeverelix®FiledPresentation
Poster presentation of Phase 1 data for Teverelix at AACE 2026
hormone-driven conditions (endometriosis, uterine fibroids)source ↗
◆Poster PresentationTeverelix®FiledPresentation
e-Poster presentation at AACE 2026 on Teverelix Phase 1 studies in healthy female volunteers
women's healthsource ↗
◆Orphan Drug DesignationSkinJect®DiscontinuedDesignation
Submitted Orphan Drug Designation application to FDA for SkinJect in Gorlin Syndrome
basal cell carcinoma in Gorlin Syndromesource ↗
●Protocol AmendmentTeverelix®FiledTrial
Optimized Phase 2 study protocol submitted to FDA for Teverelix in AURr
prevention of recurrent acute urinary retention in benign prostatic hyperplasiasource ↗
●IND SubmissionTeverelix®FiledIND
Optimized protocol submitted to FDA under existing IND
acute urinary retentionsource ↗
●Poster PresentationTeverelix®FiledPresentation
Poster presentation at AACE annual meeting demonstrating dose-dependent hormonal suppression and favorable safety profile
●Orphan Drug DesignationSkinJect®DiscontinuedDesignation
Applied for Orphan Drug Designation
Gorlin Syndromesource ↗
●Rare Pediatric DiseaseSkinJect®DiscontinuedDesignation
Intends to apply for Rare Pediatric Disease Priority Review Voucher
Gorlin Syndromesource ↗
◆Full ResultsClinical Data
Clinical Study Report (CSR) expected to be completed in Q2 2026
basal cell carcinoma (BCC)source ↗
▲Full ResultsSkinJect®DiscontinuedClinical Data
Independent KOL validation of Phase 2 results for SkinJect in nodular BCC
nodular basal cell carcinomasource ↗
◆Oral PresentationSkinJect®DiscontinuedPresentation
Business update webcast with clinical interpretation of Phase 2 data by PI Dr. Babar K. Rao
nodular basal cell carcinomasource ↗
Past FDA Catalysts and PDUFA Decisions
How MDCX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
3
Drugs Scored
rNPV / MCap
Top Drug
Top 66%
Micro Cap(rank 445 of 674)
Percentile Rank
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Teverelix DP Small moleculeNCT07457164 | Advanced Prostate Cancer | Phase 2 | NOT YET_RECRUITING | 40 | Dec 1, 2027 | ||||||
| Teverelix DP Small moleculeNCT07733934 | Acute Urinary Retention | Phase 2 | NOT YET_RECRUITING | 126 | May 1, 2028 | ||||||
| Doxorubicin-containing MNA Small moleculeNCT04928222 | Basal Cell Carcinoma | Phase 1/2 | ACTIVE NOT_RECRUITING | 25 | Jun 30, 2024 | ||||||
| teverelix TFA Small moleculeCompletedNCT04693507 | Prostatic Adenoma | Phase 2 | COMPLETED | 50 | Feb 6, 2023 | ||||||
| D-MNA 200µg Small moleculeCompletedNCT06608238 | Nodular Basal Cell Carcinoma | Phase 2 | COMPLETED | 90 | Mar 13, 2026 |
Clinical Trial Results
Readouts, endpoints and source filings for every MDCX program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| SkinJect® | Gorlin syndrome with multiple basal cell carcinoma lesions | Phase 2 | 2026-09-10 | 200 µg D-MNA patch as the lead development dose; 90 patients enrolled; all 90 completed the study without treatment discontinuations or study withdrawals.Read More | Medicus Pharma Publishes Abridged Final Phase 2 SkinJect® Clinical Study Report (CSR) Results Identifying 200 µg D-MNA Patch as the Lead Development DoseRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Smith Andrew AlasdairOfficer (Chief Operating Officer) | Grant/Award | 50,000 50,000 held | $0.00 | 03/30/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in MDCX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in MDCX for Q2 2026. | ||||
Ownership Trends
MDCX Short Interest
Shares sold short, counted twice a month.
24.24%
Short % of Float
of tradable shares sold short
43.6K
Shares Sold Short
-98.8% vs prior count
1.0 Low
Days to Cover
trading days of normal volume to buy every short share back
116.9K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How MDCX ranks across every disease it competes in
Competitive Position is a premium feature
See how MDCX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialMDCX News
MDCXMedicus Pharma to Present at BioFuture and Global Biotechnology Summit
Medicus Pharma announced that CEO Dr. Raza Bokhari will present at BioFuture 2026 and deliver a keynote at the Global Biotechnology Summit 2026. The presentations will focus on the company's advancements in targeted cancer therapeutics, particularly CD228V and SkinJect®, which are aimed at treating specific cancer types and conditions. The events will provide a platform for discussing innovations in biotechnology and precision medicine.
Read more →MDCXMedicus Pharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
Medicus Pharma Ltd. announced it has regained compliance with Nasdaq's minimum bid price requirement. The company received a Compliance Notice confirming its common shares' closing bid price was above $1.00 for ten consecutive business days. Medicus continues to focus on advancing its therapeutic assets across various global markets.
Read more →MDCX▼ -36.4%on this news· ran to -59% by day 3
Medicus Pharma Highlights Three Years of Progress and Outlines Potential Path to Long Term Value
Medicus Pharma Ltd. has marked its third anniversary by highlighting significant advancements in its portfolio, including the investigational assets CD228V and SkinJect. The company has raised approximately $90 million for clinical development and strategic acquisitions, positioning itself for potential long-term value. However, challenges such as stock-price volatility and the need for further clinical evidence remain.
Read more →MDCXMedicus Pharma Submits Optimized Teverelix® Registrational Protocol to FDA to Create Partner Ready Program in Advanced Prostate Cancer
Medicus Pharma has submitted an optimized Phase 2b/3 registration-intent protocol for Teverelix to the FDA, aiming to create a capital-efficient pathway for advanced prostate cancer treatment. This new design could significantly reduce the required patient enrollment from 1,500 to approximately 600. The company seeks to establish a partner-ready program without committing additional capital to clinical studies.
Read more →MDCXMedicus Pharma Announces Exclusive Development Focus for SkinJect® in Gorlin Syndrome Following Commercial, Clinical and Regulatory Assessment
Medicus Pharma has announced a strategic shift to focus the clinical development of SkinJect® exclusively on patients with Gorlin syndrome, following a comprehensive assessment. This decision is part of a broader capital-efficient strategy aimed at maximizing development opportunities. The FDA has authorized a pivotal study for SkinJect®, which aims to provide targeted treatment for patients suffering from multiple basal cell carcinomas.
Read more →MDCX▼ -5.3%on this news
Medicus Pharma Publishes Abridged Final Phase 2 SkinJect® Clinical Study Report (CSR) Results Identifying 200 µg D-MNA Patch as the Lead Development Dose
Medicus Pharma has published an abridged Clinical Study Report for its Phase 2 SkinJect® study, highlighting the 200 µg D-MNA patch as the lead dose. The study involved 90 patients and showed promising efficacy and safety results. The findings will inform the FDA-authorized SKNJCT-005 program targeting Gorlin syndrome patients with multiple basal cell carcinoma lesions.
Read more →MDCXMedicus Pharma Advances Transformation into a Precision Oncology-Led Biotechnology Company
Medicus Pharma is advancing its transformation into a precision oncology-focused biotechnology company, emphasizing the development of CD228V, a second-generation antibody-drug conjugate. The company aims to establish clinical proof-of-concept in melanoma while also pursuing strategic partnerships for its other programs, including SkinJect® for Gorlin syndrome and Teverelix® for acute urinary retention and endometriosis. This focused strategy is expected to enhance clinical and shareholder value.
Read more →MDCX▲ +6.9%on this news· ran to -20% by day 3
Medicus Pharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Medicus Pharma reported a net loss of $11.7 million for the second quarter of 2026. The company holds $25.2 million in cash and equivalents as of June 30. Management raised approximately $40 million through equity and debt financing during the year. Regulatory approvals were secured for SkinJect and Teverelix development programs.
Read more →MDCX▲ +9.4%on this news
Medicus Pharma Appoints Dr. Faisal Mehmud as Chief Executive Officer of Antev Limited, United Kingdom
Medicus Pharma Ltd. has appointed Dr. Faisal Mehmud as the new CEO of its UK subsidiary, Antev Limited, effective August 30, 2026. Dr. Mehmud, who also serves as Chief Medical Officer of Medicus, will lead Antev's efforts in advancing Teverelix® across various indications. His extensive experience in global pharmaceutical leadership is expected to enhance the company's strategic initiatives.
Read more →MDCXMedicus Pharma Receives UAE Department of Health (DOH) Authorization to proceed with Novel Prospective Genomics Guided Precision Medicine Study Evaluating Teverelix® in Women with Endometriosis
Medicus Pharma has received authorization from the UAE Department of Health to proceed with its PRECISION-E2 Phase 2a clinical study of Teverelix® in women suffering from moderate-to-severe endometriosis. This study aims to integrate genomic data with clinical outcomes to optimize treatment strategies. The IND approval marks a significant step in Medicus' commitment to advancing women's health therapies.
Read more →MDCX▼ -14%on this news· ran to -29% by day 3
Medicus Pharma Receives FDA “Study May Proceed” Letter for NDA-Enabling Registrational SkinJect® Study in Patients with Gorlin Syndrome
Medicus Pharma has received FDA authorization to initiate a Phase 2b clinical study for SkinJect® in patients with Gorlin Syndrome. This study aims to evaluate the efficacy and safety of the treatment, which delivers doxorubicin directly into basal cell carcinoma lesions. The FDA's recommendations have strengthened the study protocol, enhancing its scientific rigor.
Read more →MDCX▲ +16.5%on this news
Medicus Pharma Receives Positive FDA Feedback and Central IRB Approval for Optimized Phase 2 Teverelix® Novel Study in Acute Urinary Retention
Medicus Pharma has received positive feedback from the FDA and central IRB approval for its optimized Phase 2 clinical study of Teverelix in men with acute urinary retention. The redesigned study will enroll approximately 126 patients, significantly less than the previously planned 390. The study aims to evaluate the pharmacodynamic effects of Teverelix on prostate volume and urinary function, potentially accelerating clinical development.
Read more →MDCXMedicus Pharma to Showcase SkinJect® Registrational Strategy and Teverelix® Precision Medicine Program at Bio International 2026
Medicus Pharma will present its clinical development strategies at the 2026 Bio International Conference. The focus will be on SkinJect®, a treatment for basal cell carcinoma, which has shown positive Phase 2 results. Updates on Teverelix®, a GnRH antagonist for various conditions, will also be discussed. The company is preparing for regulatory meetings and pursuing orphan drug designations.
Read more →MDCX▼ -5.2%on this news· ran to +35% by day 3shared move
Medicus Pharma Announces U.S. Food and Drug Administration (FDA) Submission of Rare Pediatric Disease Designation Request for SkinJect® in Gorlin Syndrome
Medicus Pharma has submitted a Rare Pediatric Disease Designation request to the FDA for SkinJect®, a microneedle patch aimed at treating basal cell carcinoma in patients with Gorlin Syndrome. This submission follows an earlier Orphan Drug Designation application and is supported by positive Phase 2 study results. The company aims to provide a non-surgical treatment option for this rare condition.
Read more →MDCXMedicus Pharma Initiates Groundbreaking PRECISION-E2 Phase 2a Study of Teverelix® in Endometriosis utilizing the Emirati Genome Program
Medicus Pharma has announced the initiation of the PRECISION-E2 Phase 2a study to evaluate Teverelix® in women with symptomatic endometriosis. This innovative trial, leveraging the Emirati Genome Program, aims to explore treatment response variability through genomic analyses. The study is expected to provide insights that could transform endometriosis management and support future development in women's health indications.
Read more →MDCXMedicus Pharma Advances Teverelix Program Towards Registrational Development Targeting High Cardiovascular-Risk Prostate Cancer Patients with Key European Submission
Medicus Pharma Ltd. has successfully submitted a substantial modification application for its Teverelix® program, focusing on patients with advanced prostate cancer who have elevated cardiovascular risk. This submission is an important step towards registrational development and aims to optimize dosage while characterizing the drug's pharmacokinetic and pharmacodynamic profiles. Teverelix® is positioned to provide significant advantages over traditional treatments, targeting a major unmet need in the oncology market. Medicus intends to initiate patient enrollment for the Phase 2b study later this year.
Read more →MDCX▲ +7%on this newsshared move
Medicus Pharma Advances SkinJect into Registrational Development for Gorlin Syndrome
Medicus Pharma has announced the submission of Protocol SKNJCT-005 to the FDA for SkinJect, aimed at treating Gorlin Syndrome. This Phase 2b open-label study is intended to generate efficacy and safety data to support a future New Drug Application. The company aims to address the significant unmet need in Gorlin Syndrome, where current treatment options are limited. If successful, SkinJect could pioneer lesion-directed therapy for patients with this rare genetic condition.
Read more →MDCX▲ +6.7%on this news· ran to +23% by day 1
Medicus Pharma Announces $22 Million Non-Dilutive Financing
Medicus Pharma Ltd. has announced a $22 million non-dilutive financing agreement with an institutional investor. The deal will bolster the company's cash position to around $30 million, providing a projected operating runway of over 24 months. The financing includes immediate capital and a structured release of additional funds based on milestone achievements.
Read more →MDCX▲ +5.3%on this news
Medicus Pharma Reports First Quarter 2026 Financial Results and Provides Corporate Update
Medicus Pharma Ltd. has reported its financial results for Q1 2026, highlighting significant advancements in its clinical development programs, particularly for SkinJect® and Teverelix®. The company showcased positive outcomes from the Phase 2 SKNJCT-003 study for SkinJect® and received FDA clearance for a Phase 2b study of Teverelix®. However, the company also reported significant operating losses and ongoing financial concerns, although it has expanded its funding capabilities. Medicus aims to leverage its progress across multiple therapeutic areas throughout the year.
Read more →MDCX▲ +20.9%on this news
Medicus Pharma Announces Results from Pre-Specified Expanded Phase 2 SKNJCT-003 Data Analysis Demonstrating Positive Dose-Response
Medicus Pharma announced positive results from the expanded analysis of its Phase 2 SKNJCT-003 study, which evaluated the efficacy and safety of Doxorubicin Microneedle Array for treating nodular basal cell carcinoma. The analysis showed a clear dose-response relationship and reinforced the drug's therapeutic profile, paving the way for future discussions with the FDA. The findings suggest a shift in treatment approaches, potentially reducing the need for surgical interventions.
Read more →About Medicus Pharma Ltd.
Headquarters300 CONSHOHOCKEN STATE RD., W. CONSHOHOCKEN, PA, 19428
BIOPHARMAWATCH ELITE PLUS
Trade the next MDCX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime